News of Note—J&J buys up drug delivery biotech; AstraZeneca out-licenses asset; NASH biotech cancels IPO

Stork ornaments Christmas time Strasbourg France AmaWaterways Editorial use Only Photo by Susan J Young
(Susan J Young)

> Johnson & Johnson has snapped up Taris Biomedical and its drug delivery tech for treatment of bladder diseases including cancer for an undisclosed fee. J&J buys into its leading clinical-stage product, TAR-200, which uses a silicone-based drug delivery device that allows for the continuous release of medication into the bladder.

> Fortress Biotech has spun out a new biotech, known as Baergic Bio, which starts life with a licensing pact with AstraZeneca for AZD7325, an α2/3–subtype-selective GABAA positive allosteric modulator, as well as a deal with Cincinnati Children’s Hospital Medical Center to advance clinical development in certain central nervous system disorders.

> Midstage fatty liver-focused biotech Cirius Therapeutics has cancelled plans for its attempted $86 million initial public offering, with the cash earmarked for MSDC-0602K, a once-daily, oral small molecule for nonalcoholic steatohepatitis with liver scarring. The four-year-old, San Diego-based company was one known as Octeta Therapeutics and has undergone a transformation in recent years with new leadership, a new location and that new name coming in April 2017.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.